文献速递心脑血管急症重症综合管理与镇静镇痛

血浆双链DNA与脱氧核糖核酸酶活性失衡预测院外心脏骤停后死亡率

Imbalance between plasma double-stranded DNA and deoxyribonuclease activity predicts mortality after out-of-hospital cardiac arrest.
PubMed 文献 · Resuscitation · 2020-04-03
一句话结论院外心脏骤停复苏后亚急性期(24小时)双链DNA与DNase活性比值每增加1个标准差,30天死亡风险调整HR为3.59(95%CI 1.80-7.18,p<0.001)。

这项前瞻性单中心研究纳入64例院外心脏骤停复苏成功患者,在入院时(急性期)和复苏后24小时(亚急性期)测定血浆双链DNA水平和DNase活性,计算两者比值以反映双链DNA释放相对于降解能力的失衡程度,主要终点为30天死亡率。结果显示26.6%(17例)患者在30天内死亡;循环双链DNA在入院时达峰值并在24小时内下降,DNase活性在急性期与亚急性期无差异,而每单位DNase活性对应的双链DNA负荷显著下降。亚急性期双链DNA/DNase活性比值是30天死亡率的最强预测因子,每增加1个标准差的调整HR为3.59(95%CI 1.80-7.18,p<0.001)。作者认为双链DNA水平不成比例升高且未被DNase活性代偿是院外心脏骤停幸存者死亡的强预测因子,这项先导研究提示DNase活性在心脏骤停患者中可能具有保护作用。

要点

  • 院外心脏骤停复苏后24小时(亚急性期)双链DNA/DNase活性比值是30天死亡率的最强预测因子,每1个标准差调整HR 3.59(95%CI 1.80-7.18,p<0.001)。
  • 64例院外心脏骤停幸存者中26.6%(17例)在30天内死亡,入院时循环双链DNA达峰值并在24小时内下降。
  • DNase活性在急性期(入院时)与亚急性期(24小时)无差异,而每单位DNase活性对应的双链DNA负荷显著下降。
  • 作者认为双链DNA水平不成比例升高且未被DNase活性代偿是院外心脏骤停幸存者死亡的强预测因子。
  • 这项先导研究提示DNase活性在心脏骤停患者中可能具有保护作用。

适用人群与场景

  • 院外心脏骤停复苏成功(ROSC)并存活至入院的患者,共64例。
  • 研究场景为入院时(急性期)和复苏后24小时(亚急性期)两个时间点。

研究设计与关键结果

  • 研究类型为前瞻性单中心研究,纳入64例院外心脏骤停幸存者,主要终点为30天死亡率。
  • 26.6%(n=17)患者在30天内死亡。
  • 循环双链DNA在入院时达峰值,并在24小时内下降。
  • DNase活性在急性期与亚急性期无差异,而每单位DNase活性对应的双链DNA负荷显著下降。
  • 亚急性期双链DNA/DNase活性比值是30天死亡率的最强预测因子,每1个标准差的调整HR为3.59(95%CI 1.80-7.18,p<0.001)。

证据类型、等级与局限

  • 证据类型:前瞻性单中心先导研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为双链DNA水平不成比例升高且未被DNase活性代偿是院外心脏骤停幸存者死亡的强预测因子。
  • 作者指出这项先导研究提示DNase活性在心脏骤停患者中可能具有保护作用。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

AIM: Despite an increased rate of return of spontaneous circulation (ROSC) in out-of-hospital cardiac arrest (OHCA) patients, almost half of patients do not survive up to hospital discharge. Understanding pathophysiological mechanisms of post-cardiac arrest syndrome is essential for developing novel therapeutic strategies. During systemic inflammatory responses and concomitant cell death, double-stranded (ds) DNA is released into circulation, exerting pro-inflammatory effects. Deoxyribonuclease (DNase) degrades dsDNA. The role of DNase activity in OHCA survivors and impact on clinical outcome has not been analyzed yet.

METHODS: In a prospective, single-center study, dsDNA and DNase activity were determined at hospital admission (acute phase) and 24 h (subacute phase) after ROSC. The ratio between dsDNA levels and DNase activity was calculated to determine the extent of dsDNA release in relation to the patients' capacity of degradation. Thirty-day mortality was defined as study end point.

RESULTS: We enrolled 64 OHCA survivors, of whom 26.6% (n = 17) died within 30 days. A peak of circulating dsDNA was observed at admission which decreased within 24 h. DNase activity did not differ between acute and subacute phase, while dsDNA load per DNase activity significantly decreased. The ratio between dsDNA levels and DNase activity in the subacute phase was the strongest predictor of 30-day mortality with an adjusted HR per 1 SD of 3.59 (95% CI, 1.80-7.18, p < 0.001).

CONCLUSION: Disproportionally increased dsDNA levels uncompensated by DNase activity are a strong predictor of mortality in OHCA survivors. This pilot study points to a potentially protective effect of DNase activity in patients undergoing cardiac arrest.

来源:Resuscitation,查看原文。版权归原作者所有。

参考来源

  1. Ondracek AS, Hofbauer TM, Wurm R, et al. Imbalance between plasma double-stranded DNA and deoxyribonuclease activity predicts mortality after out-of-hospital cardiac arrest. Resuscitation. 2020. PMID: 32251701. doi:10.1016/j.resuscitation.2020.03.006

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。